SEPN — SEPTERNA, INC. COMMON STOCK (Healthcare >> Biotechnology)
SEPN FAQ
What is SEPN's P/E ratio?
SEPTERNA, INC. COMMON STOCK (SEPN) currently trades at a P/E ratio of 198.27.
What is SEPN's ROE?
SEPTERNA, INC. COMMON STOCK reports a Return on Equity (ROE) of -9.52%.
What is SEPN's dividend yield?
SEPTERNA, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is SEPN's Deepscope Quality Score?
Deepscope rates SEPN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SEPN?
Deepscope's AI Timing Score for SEPN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SEPN belong to?
SEPTERNA, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 36.03
Price
0.08
(0.22%)
Day Change
|
|
|---|
SEPN Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 36.03 |
| PBV / Sector |
4.28 / 4.90
|
| Earning Per Share | -0.80 |
| PE / Sector |
198.27 / 18.25
|
| PEG or PE/Growth / Sector |
-0.51 / 0.62
|
| Average 1M Daily Value |
9.48 M
|
| Average 1W Daily Value |
11.33 M
GREAT
|
| Yếu tố Kỹ thuật |
|
85% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
52% |
| Lợi tức cho nhà đầu tư |
|
8% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-16 09:59:06 |
| Symbol | SEPN |
| Name | SEPTERNA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 45.08 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,620.47 / 8,995.97 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 250 East Grand Avenue, South San Francisco, CA, United States, 94080
Phone: 650 338 3533
Website: https://septerna.com
Employees: 130
Sector: Healthcare >> Biotechnology
Description: Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google